Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

NCT ID: NCT07196280

Last Updated: 2025-09-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 10000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-01-01
• Study Completion Date: 2022-12-31

Brief Summary

To assess the impact of 5-alpha reductase inhibitors (5-ARIs) on the incidence of atherosclerotic cardiovascular disease (ASCVD) in patients with benign prostatic hyperplasia (BPH).

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD); Benign Prostatic Hypertrophy (BPH)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Interventions

5-Alpha Reductase Inhibitors

Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• patients diagnosed with BPH or users of 5-ARIs

Exclusion Criteria

• individuals who had cancer prior to the start of follow-up and those with pre-existing ASCVD

• Minimum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Chinese PLA General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Qing Yuan

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

S2022-700-02

Identifier Type: -

Identifier Source: org_study_id